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Abstract
Background:  Probimane (Pro), an anti-cancer agent originating in China, was derived from
razoxane (ICRF-159, Raz), a drug created in Britain, specifically targeting at cancer metastasis and
as a cardioprotectant of anthrocyclines. Pro and Raz are bisdioxopiperazine compounds. In this
work, we evaluated the anti-tumor and anti-metastatic effects of Pro and Raz in vivo against two
lung tumor models, one of murine origin (Lewis lung carcinoma, LLC) and one of human origin
(LAX-83).
Results: After determining the lethal dosage of Pro and Raz, we assessed and compared the
inhibitory effects of Pro and Raz against primary tumor growth and metastatic occurrences of LLC
at the dosage of LD5. Pro and Raz were active against primary tumor growth and significantly
inhibited pulmonary metastasis of LLC at same dose-ranges (inhibitory rates > 90 %). Both Raz and
Pro were effective in 1, 5, and 9 day administration schedules. Three different schedules of Raz and
Pro were effective against the primary tumor growth of LLC (35–50 %). The synergistic anticancer
effect of Raz with bleomycin (Ble) (from 41.3 % to 73.3 %) was more obvious than those with
daunorubicin (Dau) (from 33.1 % to 56.3 %) in the LLC tumor model. Pro was also seen to have
synergistic anti-cancer effects with Ble in the LLC model. Both Raz and Pro inhibited the growth of
LAX 83 in a statistically significant manner.
Conclusions: These data suggest that both Raz and Pro may have anti-tumor potentiality and Raz
and Pro have combinative effects with Ble or Dau. The potential targets of bisdioxopiperazines may
include lung cancers, especially on tumor metastasis. The anti-cancer effects of Raz and Pro can be
increased with the help of other anticancer drugs.
Background
Razoxane (ICRF-159) (Raz), first developed in UK, was
the earliest agent against spontaneous metastasis for the
murine model (Lewis lung carcinoma) in 1969 [1]. A large
volume of papers and projects have been published in the
utilities and mechanisms of Raz for anticancer actions,
like assisting radiotherapy, [2] overcoming multi-drug
resistance (MDR) of daunorubicin and doxorubicin [3],
inhibiting topoisomerase II [4] and so on. More impor-
tantly, Raz, as a cardioprotectant of anthrocyclines, has
been licensed in 28 countries in 4 continents. Since mor-
pholine groups in some structures were reported to be
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responsible for cytotoxic or modulative actions on
tumors, an anticancer agent, probimane [1,2-bis (N4-mor-
pholine-3, 5-dioxopeprazine-1-yl) propane; AT-2153,
Pro] was synthesized by introducing two morpholine
groups into Raz in China.[5]. Raz and Pro belong to bisdi-
opiperazines. Like Raz, Pro also exhibits anti-tumor activity
both in vivo and in vitro against experimental tumor mod-
els in a small scale investigation [6,7] and limited clinical
data showed that Pro  could inhibit human malignant
lymphoma even for those resistant to other anticancer
drugs [8]. Pro exhibits the same pharmacological effects as
Raz, like detoxication of Adriamycin (ADR) induced cardi-
otoxicities, and synergism with ADR  against tumors
[9,10]. We have found some novel biological effects of
Pro, like inhibiting the activity of calmodulin (CaM), a
cell-signal regulator, which can explain anticancer actions
and the combined cytotoxic effect of Pro and ADR [11].
Pro was also shown to inhibit lipoperoxidation (LPO) of
erythrocytes [12], influence tumor sialic acid synthesis
[13] and inhibit the binding of fibrinogen to leukemia
cells [14].
Lung cancer is the No 1 killer among all categories of can-
cers in urban areas in China and many Western countries.
The high mortality rate of lung cancer can easily be caused
by inducing multi-drug resistance (MDR) and by high
metastatic occurrence in clinics [15]. Since we assume that
Pro, like Raz may possess useful therapeutic potentialities,
we evaluated in vivo the chemotherapeutical parameters of
Pro and Raz for lung cancer of both murine and human
origins.
Results
Lethal toxicity of Pro and Raz in mice
The lethal dosage of Pro and Raz is tabulated in Table 1.
Since the toxicity of Pro and Raz seemed to lack sex specif-
icity in mice, we were able to combine their numbers for
LD50 and LD5 calculations. We used the approximate dos-
age of LD5 of Pro (60 mg/kg ip × 7) and Raz (20 mg/kg ip
× 7) as equitoxic dosages for further treatment studies.
Antitumor and antimetastatic effects of Pro and Raz on 
LLC
Antitumor and antimetastatic effects of Pro and Raz on
LLC are tabulated in Table 2 and Table 3. Pro and Raz at
equitoxic dosages (LD5) showed a noticeable anticancer
effect on primary tumor growth (inhibitory rates, approx-
imately 30–45 %), and significantly inhibited the forma-
tion of tumor metastases (inhibitory rates on pulmonary
metastasis > 90 %, P < 0.001). Primary tumor growth of
LLC  was inhibited more by Pro  (48 %) than by Raz
(40.3%) in a 20 day trial, whereas the inhibition of Pro
(35.7%) was slightly less than that of Raz (40 %) on an 11
day trial. Pro seems to be more persistent than Raz in
inhibiting primary tumor growth of LLC.
Antitumor effects of bisdioxopiperazines for different 
schedules and in combination with other anticancer drugs
Antitumor effects of Raz and Pro on LLC are included in
Table 4, 5, 6. We evaluated 1, 5 and 9 day administration
schedules in our study. We found that Raz and Pro were
effective in a statistically significant manner with the 3
injection schedule of the 1, 5 and 9 day administrations
on LLC. If we administered Raz to tumor-bearing mice
once on day 1, 5 and 9, there was no difference between
treatment and vehicle control. Antitumor effects of Raz in
combination with Ble on LLC (73.3 %) were better than
those in combination with Dau (56.3 %) (Table 5 and
Table 6). Pro also showed synergistic effects in combina-
tion with Ble (Table 7).
Table 1: The subacute toxicity of Pro and Raz in mice: Mouse 
survival was observed for 1 month. The numbers of mice in each 
group were 20 for each of the 5 dosages of a single agent.
Drugs Protocols LD5 mg/kg LD50 mg/kg
Probimane ip × 10 66 121
Razoxane ip × 10 23 53
Table 2: The influence of Pro and Raz on primary tumor of LLC (using Student T-test): Route: ip × 7 daily. Experiment term was 11 
days. * P < 0.05 (treatment vs vehicle control). The numbers of mice were 30 for the control group and 20 for each treatment group. 
100 % survival was observed in each group.
Compounds Dosage mg/kg/d Body weight (g) Tumor weight (g) Tumor inhibition%
Control -- 23.3/24.4 2.80 ± 0.04 --
Razoxane 20 23.3/23.4 1.61 ± 0.03* 40.0
Probimane 30 23.4/21.6 1.91 ± 0.03* 32.1
Probimane 60 23.3/23.8 1.80 ± 0.03* 35.7BMC Pharmacology 2004, 4:32 http://www.biomedcentral.com/1471-2210/4/32
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Table 3: The influence of Pro and Raz on primary and metastatic tumor of LLC: PTI (%) – Primary tumor inhibition. MFCPM – 
metastatic foci count per mouse. Route: ip × 7 every 2 days. Experiment term was 20 days, * P < 0.001(treatment vs vehicle control). 
The numbers of mice were 30 for both control group and each treatment group. 100 % survival was observed in each group.
Compounds Dosage mg/kg/d Body weigh (g) PTI(%) MFCPM
Control --- 22.8/21.4 -- 30.9 ± 7.3
Razoxane 20 22.7/21.5 40.3 1.2 ± 0.5*
Probimane 30 23.3/22.5 42.0 1.5 ± 0.5*
Probimane 60 23.3/20.3 48.0 1.0 ± 0.2*
Table 4: Antitumor effects of bisdioxopiperazines of different schedules on Lewis lung carcinoma: *Administration every 3 hours, 16 
mice were included in each testing group. **p < 0.05 (treatment vs control), Experimental term was 11 days
Compounds Dosage Schedule Tumor weight Tumor inhibition
mg/kg 1, 5, 9 administrations (g) %
Control -- -- 2.36 ± 0.05
Razoxane 80 1 time a day 2.49 ± 0.05 -5.5
Razoxane 40 1 time a day 2.32 ± 0.07 1.7
Razoxane 20 1 time a day 2.80 ± 0.06 -18.6
Razoxane 10 3 times a day* 1.51 ± 0.04** 36.0
Probimane 20 3 time a day* 1.19 ± 0.05** 49.6
Table 5: Antitumor effects of Raz on Lewis lung carcinoma in combination with daunorubicin: *Administration every 3 hours. 
Experimental term was 11 days
Compounds Dosage Schedule Tumor weight (g) Tumor inhibitions
mg/kg 1, 5, and 9 administrations %
Control 2.34 ± 0.05
Razoxane (Raz) 10 3 times a day* 1.57 ± 0.05 32.9
Daunorubicin (Dau) 2 1 time a day 1.10 ± 0.04 53.0
Raz + Dau 10 + 2 3 times/1 time a day 1.02 ± 0.04 56.4
Table 6: Antitumor effects of Raz on Lewis lung carcinoma in combination with bleomycin: * Administrate every 3 hours in one day. ** 
p < 0.01 (treatment vs vehicle control). Experimental term was 11 days
Compounds Dosage Schedule Tumor weight Tumor Inhibition
mg/kg 1, 5, and 9 administration (g) %
Control -- -- 2.46 ± 0.06
Razoxane (Raz) 10 3 times a day* 1.44 ± 0.07 41.5
Bleomycin (Ble) 15 1 time a day 1.50 ± 0.06 39.0
Raz + Ble 10 + 15 3 times + 1 time a day 0.66 ± 0.05** 73.2**BMC Pharmacology 2004, 4:32 http://www.biomedcentral.com/1471-2210/4/32
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Antitumor activity of Pro and Raz on LAX-83
The experiments showed that LAX-83 was sensitive to Raz
(40–60 mgKg-1, ip × 5) and Pro (80–100 mgKg-1 ip × 5)
with inhibitory rates of 25–32 % and 55–60 % respec-
tively (P < 0.01 vs control). CTX, as a positive anticancer
drug (40 mgKg-1 ip × 5), exhibited antitumor activities
against the growth of LAX-83 with an inhibitory rate of 84
%. Obvious necrosis in tumor tissues was observed by his-
tological evaluation of CTX and Pro treatment groups, but
Pro showed larger vacuoles than CTX. Drug inhibition on
tumor volumes were calculated and outlined in Table 8.
We have tested the 5 most commonly used anticancer
drugs – cyclophosphamide (CTX), 5-fluoruoracil (5-Fu),
methotrexate (MTX), cisplatin (DDP) and vincristine
(VCR) (Table 9). In the LAX-83 model, CTX has been
shown to be the most effective one. The anticancer effect
of Pro was the same or better than those of MTX, DDP and
as well as 5-Fu against LAX-83 tumor growth.
Discussion
Explanations of anticancer and antimetastatic mecha-
nisms of bisdioxopiperazines  are now inconclusive. The
Table 7: Antitumor effects of Pro on Lewis lung carcinoma in combination with daunorubicin or bleomycin: *Administration every 3 
hours. Experimental term was 11 days
Compounds Dosage Schedule Body weight Tumor weight (g) Tumor inhibitions
mg/Kg 1, 5, and 9 
administration
g%
Control -- -- 20.6/21.6 2.62 ± 0.08
Pro 20 3 times a day 20.6/20.8 1.45 ± 0.07 44.6
Dau 2 1 time a day 20.6/20.0 1.14 ± 0.08 56.5
Ble 15 1 time a day 20.7/21.2 1.36 ± 0.08 48.1
Pro + Dau 20 + 2 3 times/1 time a day 20.6/20.9 1.07 ± 0.05 59.2
Pro + Ble 20 + 15 3 times/1 time a day 20.7/19.8 0.59 ± 0.04 77.5
Table 8: Antitumor activities of Pro and Raz on human tumor LAX-83 using subrenal capsule assay: Route: ip × 5 daily from the day 
after surgery. * P < 0.05, ** P < 0.001 (treatment vs vehicle control). Experiment was completed within 7 days. Tumor volume = 1/2 × 
width2 × length (using T-test)
Compounds Dosage mg/kg/d No mice Body weight (g) Tumor volume (mm3) Inhibition%
Control --- 16 19.2/21.0 39.8 ± 3.2 --
Razoxane 40 12 20.8/21.5 29.7 ± 3.0* 25
Razoxane 60 12 19.8/18.8 27.2 ± 2.8* 32
Probimane 80 12 20.0/19.6 18.0 ± 2.6** 55
Probimane 100 12 20.0/20.0 15.8 ± 2.6** 60
Cyclophosphamide 40 12 21.0/20.9 6.4 ± 2.0** 84
Table 9: Antitumor activities of anticancer drugs on human tumor LAX-83 using subrenal capsule assay: Route: ip × 5 daily from the 
day after surgery. * P < 0.05, ** P < 0.001 (treatment vs vehicle control). Experiment was completed within 7 days. Tumor volume = 1/
2 × width2 × length (using T-test)
Compounds Dosage mg/kg/d No mice Body weight (g) Tumor volume (mm3) Inhibition%
Control --- 16 20.9/22.5 29.7 ± 3.2 --
Methotrexate 1.5 12 21.2/21.9 27.4 ± 3.0 7.7
Cis-platin 1.5 12 22.8/21.7 16.6 ± 2.6** 44.1
5-fluoruoracil 37.5 12 21.7/21.4 12.8 ± 2.6** 57.5
Cyclophosphamide 30.0 12 21.0/20.9 5.8 ± 2.3** 80.5
Vincristine 0.3 12 20.8/20.8 7.6 ± 2.2** 74.4BMC Pharmacology 2004, 4:32 http://www.biomedcentral.com/1471-2210/4/32
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present explanation for the anticancer mechanisms of Raz
has been attributed to antiangiogenesis and topoisomer-
ase II inhibition.[16] Since the antimetastatic activities of
Raz and Pro were much stronger than those actions against
primary tumor growth, this special targeting on metastasis
ought to be more useful in clinical cancer treatment. Raz
and Pro show typical characteristics of antiangiogenesis
agents, which target small nodule of tumors. Meanwhile,
recent reports on drugs targeting angiogenesis indicate that
most anti-vascular drugs have low or even no effects on
most cancers when they are used alone in clinics, but they
show synergistic effects in combination with other anti-
cancer drugs. [17,18] Our study shows synergistic antican-
cer actions of Raz and Pro with Ble or Dau basing on this
theory. Previous work showed that Pro  and  Raz  could
reduce the cardiotoxicity of anthrocycline,[1,9,10] so we
may reasonably deduce that they can also reduce the cyto-
toxicity of anthrocyclines. The data in our study suggests
that the synergistic effects of Raz with anthrocyclines are
present, but not as potent as those with Ble.
Since we have tested the antitumor activity of clinically
available anticancer drugs (CTX, 5-Fu, MTX, DDP and
VCR) against LAX-83, CTX being the best one, two bisdi-
oxopiperazines studied on this work show overall similar
anticancer effective as commonly used drugs. Although
the anticancer effects of CTX and VCR are better than
those of Pro, for other commonly used drugs, such as
DDP, MTX and 5-Fu, the antitumor effects are no better
than those of Pro. Since the antitumor effects of MTX and
DDP are even less effective than those of Pro and Raz, we
suggest that anticancer effects of Pro and Raz are within
the effective anticancer ranges of commonly available
anticancer drugs.
The other useful property of Pro is that it is the most water-
soluble among the bisdioxopiperazines. Most bisdioxopipera-
zines  are less water-soluble and given orally in clinics.
Although oral administration is easy for patients, bioa-
vailability varies from patient to patient. For some
patients who have a poor absorption of bisdioxopiperazines
in oral administration, Pro can be injected iv to maintain
stable drug levels. Our previous work showed that Pro
could strongly accumulate in tumor tissue while Pro levels
in other tissues decrease rapidly [19]. Presently, a stereo-
isomer of Raz, (dexrazoxane, ICRF-187), a water-soluble
Raz, is being reinvestigated and has aroused the interests
of clinical oncologists. Phase III clinical studies are
currently underway in the US. More importantly, ICRF-
187 was licensed in 28 countries in 4 continents. This
work shows a noticeable inhibition of Pro and Raz on lung
cancers and suggests possible usage of Raz and Pro on lung
cancer in clinics.
Conclusions
The advantages of bisdioxopiperazines in clinical treatment
of lung cancers are as follows: (i) Pro and Raz can inhibit
the growth of lung cancers, with and without the help of
other anticancer drugs, like Dau and Ble; (ii) like Raz, Pro
strongly inhibits spontaneous pulmonary metastasis of
LLC; (iii) since Pro can inhibit CaM [11], a calcium acti-
vated protein that's associated with MDR and metastatic
phenotypes, synergistic anticancer effects of Pro and Raz
can be expected in combination with other anti-cancer
drugs, like Dau or Ble. Now, new concepts of the relation-
ship between tumor metastasis and MDR in cancers have
been stated,[20] whereas bisdioxopiperazines  can inhibit
both tumor metastasis and MDR. As a counterpart of Raz,
Pro  might be of interest and have chemotherapeutic
potential in clinics.
Methods
Drugs and animals
Cyclophosphomide (CTX), daunorubicin (Dau) and ble-
omycin (Ble), 5-fluororacil (5-Fu), vincristine (VCR), cis-
platin (DDP), methotrexate (MTX) were purchased from
Shanghai Pharmaceutical Company. Pro and Raz were
prepared by Department of Medicinal Chemistry, Shang-
hai Institute of Materia Medica, Chinese Academy of Sci-
ences. C57BL/6J and Kun-Min strain mice were purchased
from Shanghai Center of Laboratory Animal Breeding,
Chinese Academy of Sciences. Nude mice (Swiss-DF),
taken from Roswell Park Memorial Institute, USA, were
bred in Shanghai Institute of Materia Medica, Chinese
Academy of Sciences under a specific pathogen free condi-
tion. Human pulmonary adenocarcinoma xenograft
(LAX-83)[21] and Lewis lung carcinoma (LLC) were seri-
ally transplanted in this laboratory. All animal experi-
ments were conducted in compliance with the Guidelines
for the Care and Use of Research Animals, NIH, estab-
lished by Washington University's Animal Studies Com-
mittee. Bouin's solution consists of water saturated with
picric acid: formaldehyde: glacial acetic acid (75: 20: 5, v/
v/v).
Lethal dosage determination in mice
Mice of Kun-Min strain (equal amount of male and
female) were ip injected with Pro and Raz daily for 10 suc-
cessive days. The deaths of mice were counted after 1
month. Lethal dosage of agents was calculated by Random
Probity tests.
Antitumor and antimetastatic studies of LLC
C57BL/6J mice were implanted sc with LLC (2 × 106 cells)
from donor mice. The mice were injected intraperito-
neally with drugs daily or every two days for 7 injections.
On day 11 or day 20, mice were sacrificed, and locally
growing tumors were separated from skin and muscles
and weighed, and lungs of host mice were placed into aBMC Pharmacology 2004, 4:32 http://www.biomedcentral.com/1471-2210/4/32
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Bouin's solution for 24 h, and then the lung samples were
submerged into a solution of 95 % alcohol for 24 h.
Finally, the numbers of extruding metastatic foci in lungs
were counted.
Antitumor actions of different schedules and in 
combinations with different drugs
C57BL/6J mice were implanted sc with LLC (2 × 106 cells)
from donor mice. Mice were injected intraperitoneally
with drugs on day 1, 5, 9. Single injection or 3 injections
every 3 hours were used. Tumors were separated and
weighed on day 11.
Antitumor activity study of human tumors
Nude mice were inoculated with LAX-83 under the renal
capsule (SRC method).[22] Nude mice were injected
intraperitoneally with drugs daily during next five days
after inoculation of LAX-83. Then nude mice were sacri-
ficed, and their kidneys were taken out for measurement
of tumor sizes using a stereomicroscope a week after trans-
plantation. Tumor volume was calculated as 1/2(ab2)
where a and b are their major and minor axes of the lump.
Kidneys with tumors were paraffin-embedded, sliced and
hematoxylin dyed. The tumor tissues were then observed
from a light microscope.
Statistical analysis
Student's t-test was used to assess the differences between
control and drug treatment groups of above methods.
List of abbreviation used are
Pro, probimane; Raz, razoxane; CaM, calmodulin; LPO,
lipoperoxidation; Dau, daunorubicin; Ble, bleomycin;
LLC, Lewis lung carcinoma, LAX-83; a lung adenocarci-
noma xenograft; ADR, adriamycin;
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